8-K
Immunome Inc. (IMNM)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of theSecurities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 14, 2024
Immunome,Inc.
(Exact name of registrant as specified in itscharter)
| Delaware | 001-39580 | 77-0694340 |
|---|---|---|
| (state or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer IdentificationNo.) |
| 18702 N. Creek Parkway, Suite 100 Bothell , WA | 98011 | |
| --- | --- | |
| (Address of principal executive offices) | (ZipCode) |
Registrant’s
telephone number, including area code: (610) 321-3700
N/A
(Former name or formeraddress, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ¨ | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title<br> of each class | Trading<br> Symbol | Name<br> of each exchange<br> on which registered |
|---|---|---|
| Common Stock, $0.0001 par value per share | IMNM | The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and FinancialCondition.
On May 14, 2024, Immunome, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2024 and business update in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.
Item 9.01 Financial Statements and Exhibits.
(d)
| Exhibit<br><br> <br>Number | Description |
|---|---|
| 99.1 | Press Release dated May 14, 2024 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: May 14, 2024 | Immunome, Inc. | |
|---|---|---|
| By: | /s/ Max Rosett | |
| Name: | Max Rosett | |
| Title: | Chief Financial Officer |
Exhibit 99.1
ImmunomeReports First Quarter 2024 Financial Results and Provides Business Update
| - | Integration of AL102 and IM-1021 completed |
|---|---|
| - | Topline data for Phase 3 RINGSIDE trial of AL102 expected in second half of 2025 |
| --- | --- |
| - | IM-1021 and IM-3050 IND submissions expected in first quarter of 2025 |
| --- | --- |
BOTHELL, Wash. – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.
“Immunome continues to build momentum. We have completed the integration of AL102 and are executing activities necessary for regulatory submissions,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer. “We have also completed the integration of IM-1021 and are advancing that program and IM-3050 towards clinical trials.”
Dr. Siegall continued, “In addition, we are working internally to design and develop additional next-generation ADC technology. Those efforts are complemented by our ongoing business development efforts, which seek to identify and procure high-quality technologies and clinical programs. Both our internal and external efforts are focused on expanding Immunome’s pipeline with additional programs that have first-in-class or best-in-class potential and can improve the lives of cancer patients.”
Pipeline Highlights
The purchase of AL101 and AL102 from Ayala Pharmaceuticals closed on March 25, 2024. Full enrollment for the Phase 3 RINGSIDE Part B study of AL102 for the treatment of desmoid tumors was completed in February 2024. Immunome expects to report topline data for RINGSIDE Part B in the second half of 2025. In parallel, Immunome continues to perform additional manufacturing and pharmacology work required to support a new drug application filing for AL102.
Immunome anticipates submitting INDs for two preclinical candidates in the first quarter of 2025: IM-1021, a ROR1 ADC, and IM-3050, a FAP-targeted RLT.
FirstQuarter 2024 Financial Results
| · | As<br> of March 31, 2024, cash, cash equivalents and marketable securities totaled $309.7 million.<br> Immunome’s current cash runway is expected to extend into 2026. |
|---|---|
| · | Research<br> and development expenses for the quarter ended March 31, 2024 were $15.4 million, including<br> stock-based compensation costs of $0.4 million. |
| --- | --- |
| · | In-process<br> research and development expenses for the quarter ended March 31, 2024 were $112.0 million.<br> These expenses were related to Immunome’s acquisition of AL101 and AL102 from Ayala<br> Pharmaceuticals, Inc. and the exclusive license of IM-1021 and related ADC platform<br> technology from Zentalis Pharmaceuticals, Inc., both of which closed in the quarter<br> ended March 31, 2024. |
| --- | --- |
| · | General<br> and administrative expenses for the quarter ended March 31, 2024 were $6.0 million,<br> including stock-based compensation expense of $1.8 million. |
| --- | --- |
| · | Immunome<br> reported a net loss of $129.5 million, or basic and diluted net loss per share attributable<br> to common stockholders of $2.51, for the quarter ended March 31, 2024. |
| --- | --- |
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including small molecules, ADCs, and RLTs. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets.
For more information, visit www.immunome.com or follow us on Twitter and LinkedIn.
Cautionary Statement Regarding Forward-LookingStatements
Certain statements contained in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). We use words such as “may,” “could,” “potential,” “will,” “plan,” “believe,” “expect,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA. These forward-looking statements include, but are not limited to, Immunome’s expectation to report topline data for the ongoing Phase 3 RINGSIDE Part B trial of AL102 in the second half of 2025; Immunome’s expected timeline for submitting INDs for IM-3050 and IM-1021 in the first quarter of 2025; Immunome’s expected cash runway; Immunome’s ability to expand its pipeline through both internal and external efforts; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Such forward-looking statements are based on Immunome’s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, the risk that Immunome will not be able to realize the benefits of its strategic transactions; Immunome’s ability to grow and successfully execute on its business plan, including the development and commercialization of its pipeline and integration of newly acquired assets; changes in the applicable laws or regulations; the possibility that Immunome may be adversely affected by other economic, business, and/or competitive factors; the risk that regulatory approvals for Immunome’s programs and product candidates are not obtained, are delayed or are subject to unanticipated conditions; the risk that pre-clinical data may not be predictive of clinical data; the risk that interim results of a clinical trial do not necessarily predict final results; potential delays in the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; the risk that Immunome’s product and development candidates fail to achieve their intended endpoints; the complexity of numerous regulatory and legal requirements that Immunome needs to comply with to operate its business; the reliance on Immunome’s management; the prior experience and successes of the Immunome’s management team not being indicative of any future success; uncertainties related to Immunome’s capital requirements and Immunome’s expected cash runway; the failure to obtain, adequately protect, maintain or enforce Immunome’s intellectual property rights; and other risks and uncertainties indicated from time to time described in in Immunome’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 26, 2024, in ARS Pharma’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, being filed with the SEC today, and in Immunome’s other filings with the SEC. Immunome cautions that the foregoing list of factors is not exclusive and not to place undue reliance upon any forward-looking statements which speak only as of the date made. Moreover, Immunome operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Except as required by law, Immunome does not undertake any obligation to update publicly any forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in their expectations.
Investor Contact:
Max Rosett
Chief Financial Officer
investors@immunome.com
Immunome, Inc.
Consolidated BalanceSheets
(in thousands, exceptshare and per share amounts)
| March 31, 2024 | December 31, 2023 | |||||
|---|---|---|---|---|---|---|
| Assets | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 269,723 | $ | 98,679 | ||
| Marketable securities | 39,983 | 39,463 | ||||
| Prepaid expenses and other current assets | 3,620 | 6,561 | ||||
| Total current assets | 313,326 | 144,703 | ||||
| Property and equipment, net | 4,302 | 2,073 | ||||
| Operating right-of-use assets | 1,458 | 1,564 | ||||
| Restricted cash | 100 | 100 | ||||
| Other long-term assets | 568 | 100 | ||||
| Total assets | $ | 319,754 | $ | 148,540 | ||
| Liabilities and stockholders’ equity | ||||||
| Current liabilities: | ||||||
| Accounts payable | $ | 7,179 | $ | 3,311 | ||
| Accrued expenses and other current liabilities | 10,844 | 8,025 | ||||
| Deferred revenue, current | 12,745 | 10,493 | ||||
| Total current liabilities | 30,768 | 21,829 | ||||
| Deferred revenue, non-current | 2,208 | 5,489 | ||||
| Other long-term liabilities | 1,206 | 1,340 | ||||
| Total liabilities | 34,182 | 28,658 | ||||
| Commitments and contingencies (Note 8) | ||||||
| Stockholders’ equity: | ||||||
| Preferred stock | — | — | ||||
| Common stock | 6 | 4 | ||||
| Additional paid-in capital | 637,861 | 342,663 | ||||
| Accumulated other comprehensive income | 4 | 22 | ||||
| Accumulated deficit | (352,299 | ) | (222,807 | ) | ||
| Total stockholders’ equity | 285,572 | 119,882 | ||||
| Total liabilities and stockholders’ equity | $ | 319,754 | $ | 148,540 |
Immunome, Inc.
Consolidated Statementsof Operations
(in thousands, exceptshare and per share amounts)
| **** | Three Months Ended March 31, | **** | ||||
|---|---|---|---|---|---|---|
| **** | 2024 | **** | 2023 | **** | ||
| Collaboration revenue | $ | 1,029 | $ | 2,364 | ||
| Operating expenses: | ||||||
| In-process research and development | 111,954 | — | ||||
| Research and development | 15,369 | 3,913 | ||||
| General and administrative | 6,005 | 2,922 | ||||
| Total operating expenses | 133,328 | 6,835 | ||||
| Loss from operations | (132,299 | ) | (4,471 | ) | ||
| Other income: | ||||||
| Interest income | 2,807 | 201 | ||||
| Total other income | 2,807 | 201 | ||||
| Net loss | $ | (129,492 | ) | $ | (4,270 | ) |
| Per share information: | ||||||
| Net loss per share, basic and diluted | $ | (2.51 | ) | $ | (0.35 | ) |
| Weighted-average shares outstanding, basic and diluted | 51,544,383 | 12,182,478 | ||||
| Comprehensive loss | ||||||
| Net loss | $ | (129,492 | ) | $ | (4,270 | ) |
| Unrealized loss on marketable securities | (18 | ) | — | |||
| Comprehensive loss | $ | (129,510 | ) | $ | (4,270 | ) |